The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
Open accessAbstract
Objective: To assess the association between risk of venous thromboembolism and use of different types of hormone replacement therapy. Design: Two nested case-control studies. Setting: UK general practices contributing to the QResearch or Clinical Practice Research Datalink (CPRD) databases, and linked to hospital, mortality, and social deprivation data. Participants: 80 396 women aged 40-79 with a primary diagnosis of venous thromboembolism between 1998 and 2017, matched by age, general practice, and index date to 391 494 female controls. Main outcome measures: Venous thromboembolism recorded on general practice, mortality, or hospital records. Odds ratios were adjusted for demographics, smoking status, alcohol consumption, comorbidities, recent medical events, and other prescribed drugs. Results: Overall, 5795 (7.2%) women who had venous thromboembolism and 21 670 (5.5%) controls had been exposed to hormone replacement therapy within 90 days before the index date. Of these two groups, 4915 (85%) and 16 938 (78%) women used oral therapy, respectively, which was associated with a significantly increased risk of venous thromboembolism compared with no exposure (adjusted odds ratio 1.58, 95% confidence interval 1.52 to 1.64), for both oestrogen only preparations (1.40, 1.32 to 1.48) and combined preparations (1.73, 1.65 to 1.81). Estradiol had a lower risk than conjugated equine oestrogen for oestrogen only preparations (0.85, 0.76 to 0.95) and combined preparations (0.83, 0.76 to 0.91). Compared with no exposure, conjugated equine oestrogen with medroxyprogesterone acetate had the highest risk (2.10, 1.92 to 2.31), and estradiol with dydrogesterone had the lowest risk (1.18, 0.98 to 1.42). Transdermal preparations were not associated with risk of venous thromboembolism, which was consistent for different regimens (overall adjusted odds ratio 0.93, 95% confidence interval 0.87 to 1.01). Conclusions: In the present study, transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed. Transdermal treatment appears to be underused, with the overwhelming preference still for oral preparations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Multiple Imputation of Missing Values
Royston, P. (2004) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0400400301 · Cited by 2,340
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650 · cited 2×
“5 Findings from randomised controlled trials summarised in a Cochrane systematic review(4) were based mainly on the Women’s Health Initiative trial of women in the United States, who were predominantly in relatively good health.(6) The review reported that increased risk was associated with oestrogen only oral prepara…”
Breast cancer and hormone-replacement therapy: the Million Women Study
Beral, V., Banks, E., Reeves, G., & Bull, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14596-5 · Cited by 1,273
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864
Scarabin, P.-Y., Oger, E., & Plu-Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 714
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Grodstein, F., Stampfer, M. J., Goldhaber, S. Z., Manson, J. E., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hennekens, C. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07308-4 · Cited by 571
Cited by
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
(2020) · Menopause · doi:10.1097/gme.0000000000001609 · Cited by 531
Management of Menopausal Symptoms: A Review
Crandall, C. J., Mehta, J. M., & Manson, J. E. (2023) · JAMA · doi:10.1001/jama.2022.24140 · Cited by 316
Premature ovarian insufficiency: an international menopause society white paper
Panay, N., Anderson, R. A., Nappi, R. E., Vincent, A. J., Vujovic, S., Webber, L., & Wolfman, W. (2020) · Climacteric · doi:10.1080/13697137.2020.1804547 · Cited by 297
Hormone therapy for postmenopausal women
Pinkerton, J. V. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1714787 · Cited by 220
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Hormone replacement therapy – Current recommendations
Vigneswaran, K., & Hamoda, H. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.12.001 · Cited by 151
Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review
Goldštajn, M. Š., Mikuš, M., Ferrari, F. A., Bosco, M., Uccella, S., Noventa, M., Török, P., Terzic, S., Laganà, A. S., & Garzon, S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06647-5 · Cited by 111
Transgender patients and the role of the coagulation clinician
Connors, J. M., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14626 · Cited by 42
Jain, J., Kwan, D., & Forcier, M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02253 · Cited by 32
Altered Metabolism and DAM-signatures in Female Brains and Microglia with Aging
Cleland, N. R. W., Potter, G. J., Buck, C., Quang, D., Oldham, D., Neal, M., Saviola, A., Niemeyer, C. S., Dobrinskikh, E., & Bruce, K. D. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148772 · Cited by 26
A current perspective into young female sex hormone replacement: a review
Giordano Imbroll, M., & Gruppetta, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1816820 · Cited by 7
Metadata
- Authors
- Vinogradova, Y., Coupland, C., & Hippisley-Cox, J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2019-01-09
- Volume
- 364
- Pages
- k4810
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2909075990
- Cited by
- 433
- References
- 28
- FWCI
- 40.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.